Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
J Opioid Manag ; 17(7): 167-170, 2021.
Article in English | MEDLINE | ID: mdl-34520038

ABSTRACT

Buprenorphine (BPN), FDA approved for opioid use disorder (OUD), requires an induction protocol for the patient in mild to moderate withdrawal. This can be problematic in outpatient practice due to complicated medical management. An emerging technique in literature uses a novel approach, called microinduction. In this method, escalating microdoses of BPN are administered, without requiring the patient to stop the opioid agonist. Our addiction treatment center used a microdosing technique to transit patients from methadone to BPN, without requiring opioid abstinence. Our case series is novel as it was outpatient microinduction from methadone to BPN in 7 days or less.


Subject(s)
Buprenorphine , Opioid-Related Disorders , Analgesics, Opioid/adverse effects , Buprenorphine/therapeutic use , Humans , Methadone/therapeutic use , Opiate Substitution Treatment , Opioid-Related Disorders/drug therapy , Outpatients
SELECTION OF CITATIONS
SEARCH DETAIL
...